Navigation Links
New medications show promise in treating drug-resistant prostate cancer
Date:4/7/2009

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

Of 30 men who received low doses of one the drugs in a multisite phase I/II trial designed to evaluate safety, 22 showed a sustained decline in the level of prostate specific antigen (PSA) in their blood. Phase III clinical trials are planned to evaluate the drug's effect on survival in a large group of patients with metastatic prostate cancer.

The drugs are second-generation antiandrogen therapies that prevent male hormones from stimulating growth of prostate cancer cells. The new compounds manufactured by the pharmaceutical company Medivation and known as MDV3100 and RD162 appear to work well even in prostate cells that have a heightened sensitivity to hormones. That heightened sensitivity makes prostate cancer cells resistant to existing antiandrogen therapies.

The drugs were discovered in the laboratory of Howard Hughes Medical Institute investigator Charles Sawyers at Memorial Sloan-Kettering Cancer Center in collaboration with chemist Michael Jung at UCLA. He and his colleagues described the development of the drugs and initial testing in an article posted online April 9, 2009, in Science Express, which provides electronic publication of selected Science articles in advance of print. Sawyers's team collaborated on the studies with researchers from the University of California Los Angeles, Oregon Health and Science University, University of Washington and Medivation.

About 186,000 new cases of prostate cancer are diagnosed each year in the United States. The male hormones testosterone and dihydrotestosterone -- also known as androgens -- spur the growth of prostate cells, and drugs that block the receptors for these hormones are the most common treatment for the disease in its advanced, metastatic stage. Antiandrogen drugs, such as bicalutamide, supp
'/>"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Device prevents potential errors in childrens medications
2. Study of successful drug targets could hasten development of new medications
3. Genetic variant mimics effect of heart failure medications
4. Hypertension and cholesterol medications present in water released into the St. Lawrence River
5. Innovative civil engineering application promises cleaner waters
6. New CPR promises better results by compressing abdomen, not Chest
7. Tiny tubes and rods show promise as catalysts, sunscreen
8. New genetic research into nicotine addiction shows promise for personalized treatment
9. Genetic ancestral testing cannot deliver on its promise, study warns
10. Sweet potato shines as new promise for small enterprise and hunger relief in developing countries
11. Summer-dormant tall fescue grass shows promise for pasture improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... successful, a new discovery published in The FASEB ... scientific leap toward human tissue regeneration and engineering. In ... to support a major paradigm shift in this specialty ... graft before implantation are the building blocks of tissue, ...
... organizations released a new study recommending a disease screening ... to ensure the safety of people and wildlife alike. ... species, the yacare caiman and broad-snouted caiman, both of ... The research team sought to assess the presence of ...
... May 13, 2010 (Toronto) A new study ... found a gene connected with a type of intellectual disability ... Vincent has identified this gene that, when defective, leads to ... 2011 issue of Cell . This international study ...
Cached Biology News:Yale scientists discover new method for engineering human tissue regeneration 2Wildlife Conservation Society recommends health measures for Argentina's caiman ranches 2CAMH researcher discovers new gene that causes intellectual disability 2
(Date:5/5/2015)... May 5, 2015  Renova™ Therapeutics, a biopharmaceutical ... failure and other chronic diseases, has engaged RAND ... designed to reflect the healthcare patterns of multiple ... will be used to characterize the impact the ... on those groups of patients and the overall ...
(Date:5/5/2015)... 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... President and Chief Executive Officer, will present live ... DATE:  Thursday, May 7, 2015     TIME:  11:30 am ET/8:30 ... click the red "register/ watch presentations" button ... event where investors are invited to ask the ...
(Date:5/5/2015)... May 05, 2015 A comment period ... wide range of key photonics technologies – regulations that ... of U.S. industry. To help the community understand and ... May on the proposed changes to U.S. Munitions ... by International Traffic in Arms Regulations (ITAR). , For ...
(Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ) ... Laboratory, Molecular Diagnostics and Genomic Testing Services Market ... Version" report to their offering. ... molecular diagnostics and pharmacogenics hold the promise of ... is moving out of the national and regional ...
Breaking Biology Technology:RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... FRAZER, Pa., Sept. 21 Cephalon, Inc. (Nasdaq:,CEPH) ... Drug Application (NDA) to,the U.S. Food and Drug ... the treatment of patients with chronic,lymphocytic leukemia (CLL). ... disease with an estimated 15,000 new cases diagnosed ...
... CLARA, California, September 21, ChemAxon, a software solutions ... A ) today announced an,agreement to maintain the ... ChemAxon,s software suite. Agilent acquired,the Kalabie ELN from ... between Klee and ChemAxon to Agilent and ChemAxon. ...
... to reduce catheter-related infections, REDMOND, Wash., ... biomaterial solutions to enhance the biocompatibility and,performance ... announced,a partnership deal with Strategic Applications Inc. ... catheter and infusion devices.,Healionics, deal with SAI ...
Cached Biology Technology:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook 2Healionics Corporation Announces Partnership to Develop and Distribute STARcuff(TM) 2
... Slotted migration Chamber lid allows easy gel ... One-touch connectors for easy set up between power ... prevents current flow if the lid is removed ... and durability., Remote control can be ...
... ProFound Label Transfer Sulfo SBED Protein:Protein ... known as Label Transfer has rapidly gained ... protein interaction discovery. A growing number of ... Biotin Label Transfer Reagent to study a ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
... label transfer is fast emerging as a ... and confirmation. Until now, only amino groups ... label transfer reagents such as our Sulfo-SBED. ... Mts-Atf-LC-Biotin, are exciting additions to the protein ...
Biology Products: